What dose of p021 do sources report?
| Study | Dose and schedule | Animals |
|---|---|---|
| Baazaoui and Iqbal1 | 60 nmol/g feed, from 3 months of age to 21 months | 32 P021-treated and 35 vehicle-treated female 3xTg-AD mice, and 41 female wild-type mice |
| Wei et al.3 | 60 nmol peptide/g diet, fed to mothers from prenatal day 8 to postnatal day 21 | Offspring of wild-type mothers (10 vehicle, 17 P021) and of 3xTg-AD mothers (12 vehicle, 18 P021) |
| Mottolese et al., diet2 | 60 nmol/g diet for 70 days from postnatal day 21, about 2.7 g diet a day | 39 Cdkl5 KO male mice across the paper (17 wild-type, 22 knockout) |
| Mottolese et al., injection2 | 750 nmol per mouse in saline, injected intraperitoneally daily for 30 days | 4-month-old Cdkl5 knockout male mice |
Doses and schedules in animals
The table is set at the top of the page
A search of DailyMed, ClinicalTrials.gov and PubMed returned no human dose, schedule, cycle, stepping or trial of p021. The doses in the table differ by route, diet or intraperitoneal injection, and none is a human dose.2 Kazim and colleagues fed female 3xTg-AD and wild-type mice a p021 or vehicle diet for 12 months, starting at 9 to 10 months of age.4
Form, route and mixing
Mottolese and colleagues describe p021 as a tetra-peptide derived from CNTF, with effects on neurogenesis and synaptic plasticity reported in preclinical models of brain disorders.2 DailyMed returned no p021 label, tablet, capsule or powder strength. A review calls it a small molecular weight compound that crosses the blood-brain barrier, with pharmacokinetics suited to oral administration,5 and a mouse paper calls it water-soluble.6 Earlier work gave it by subcutaneous injection to mice and by oral gavage to rats.1 DailyMed also returned no mixing instructions or storage conditions for p021. With no human concentration, no U-100 syringe mark or calculator figure can be worked.
Frequently asked questions
What side effects has p021 shown?
Baazaoui and Iqbal report that p021 did not show any severe side effects or safety issues in their preclinical study of almost 2 years in female 3xTg-AD mice.1 Searches returned no human safety data.
Is p021 the same as CNTF?
No. A Down syndrome mouse paper by Kazim and colleagues describes p021 as derived from CNTF, and says recombinant CNTF has been shown to cause anorexia, skeletal muscle loss, hyperalgesia, severe cramps, and muscle pain in humans.6
References
- PubMed Central. Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound. 2017. pmc.ncbi.nlm.nih.gov
- PubMed Central. Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder. 2024. pmc.ncbi.nlm.nih.gov
- PubMed Central. Prenatal to early postnatal neurotrophic treatment prevents Alzheimer-like behavior and pathology in mice. 2020. pmc.ncbi.nlm.nih.gov
- PubMed. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. 2014. pubmed.ncbi.nlm.nih.gov
- PubMed Central. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer’s disease. 2016. pmc.ncbi.nlm.nih.gov
- PubMed Central. Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer’s-like memory deficits in the Ts65Dn mouse model of Down syndrome. 2017. pmc.ncbi.nlm.nih.gov